Clinical Trials Directory

Trials / Completed

CompletedNCT06119035

Insulin Modelling Based on Plasma Glucose Measures Via a Minimally-Invasive Glucose Sensor

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Singapore Institute of Food and Biotechnology Innovation · Other Government
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Accepted

Summary

The study aims to evaluate insulin as a potential biomarker for prediabetes in Singapore Chinese subjects.

Detailed description

The prevalence of type 2 diabetes (T2DM) in Singapore is expected to increase from 400,000 to 1,000,000 individuals by 2050, resulting in nearly US$2 billion in economic costs. Pre-diabetes is defined as an intermediate state of hyperglycemia where blood glucose levels are elevated but are below the diagnostic levels of diabetes. In Singapore, approximately 1 in 7, or 430,000 residents are estimated to be pre-diabetic, and globally this number is estimated at 7.3% of adults (equivalent to 352.1 million individuals). Up to 70% of pre-diabetics eventually develop overt T2DM; however, pre-diabetes may be reversible with early detection, providing a window for opportune disease interception. While blood glucose is currently used to detect pre-diabetes, homeostatic mechanisms can maintain normal blood glucose levels and mask the detection of pre-diabetes until overt hyperglycemia is exhibited. In contrast, numerous studies have demonstrated that insulin levels increase markedly in pre-diabetes, even as marginal changes are observed in glucose levels. In this study, the investigator aims to determine if dynamic insulin levels observed during an oral glucose tolerance test are more sensitive than glucose alone in detecting prediabetes in a Singapore Chinese population.

Conditions

Interventions

TypeNameDescription
OTHERSingle dose of 75 grams glucose in 200ml waterConsume single dose of 75 grams glucose in 200ml water

Timeline

Start date
2023-11-06
Primary completion
2024-01-12
Completion
2024-01-12
First posted
2023-11-07
Last updated
2024-02-02

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT06119035. Inclusion in this directory is not an endorsement.